BIWAKO
Lyon 06, 69006, France
NCT Number: NCT07354555
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.
No intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Lyon 06, 69006, France
This retrospective observational study aims to determine the feasibility of assembling a cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma and linking these materials with associated clinical and pathological data. All samples originate from routine diagnostic procedures performed as part of standard clinical care; no prospective interventions or additional tissue collection are involved.
The study evaluates whether archived FFPE specimens and corresponding clinical information can be systematically identified, retrieved, and abstracted using a predefined standardized workflow. Histopathological review and immunohistochemical markers routinely assessed during diagnostic work-up (CD138, CD56, MUM1, light chains) will be used to confirm the diagnosis and describe tumor features. Feasibility will be defined by the proportion of screened cases for which both adequate FFPE material and sufficient clinical data are available to allow inclusion.
The purpose of the study is to generate a structured dataset enabling future biomarker research and to assess whether the operational workflow used for case identification, data abstraction, and sample processing can be reliably scaled for larger retrospective cohorts.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
Number of participants who meet both criteria:
Feasibility will be quantified by reporting the proportion of eligible participants among all patients screened for potential inclusion.
Time frame: Baseline
Percentage of cases showing immunoreactivity for selected markers based on standard immunohistochemistry performed during diagnostic work-up. Marker expression is recorded as positive or negative according to predefined laboratory thresholds.
Time frame: Baseline
Categorization of EMD cases according to the anatomical origin of the archived tissue sample (e.g., soft tissue, liver, CNS, lymph node). Measurement is performed by reviewing sample metadata recorded at the time of diagnostic tissue processing.
Contact information is provided by the study sponsor or research team.
BIWAKO
Industry
Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma Extramedulary Disease
Acronym: MMExFFPE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07319897
Blood Protein Disorders, Cardiovascular Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07665307
Blood Protein Disorders, Cardiovascular Diseases
San Francisco, California, United States
View Trial DetailsNCT07600151
Blood Protein Disorders, Cardiovascular Diseases
Hamburg, Germany
View Trial DetailsNCT07482761
Blood Protein Disorders, Cardiovascular Diseases
Lyon, France
View Trial Details